Literature DB >> 30398294

The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease.

Zobair Younossi1,2, Georgios Papatheodoridis3, Patrice Cacoub4,5, Francesco Negro6, Heiner Wedemeyer7, Linda Henry8, Angelos Hatzakis9,10.   

Abstract

Treatment of hepatitis C virus (HCV) infection has been revolutionized with the introduction of pangenotypic, interferon- and ribavirin-free regimens associated with high cure rates and a low side effect profile. Additionally, there is evidence that HCV cure reduces HCV complications, improves patient-reported outcomes and is cost-saving in most western countries in the long term. This is a review of the comprehensive burden of HCV and the value of eliminating HCV infection. With the introduction of the interferon-free all-oral, once a day pill treatment regimen for the cure of HCV, the potential to eliminate HCV by 2030 has become a possibility for some regions of the world. Nevertheless, there are barriers to screening, linkage to care, and treatment in many countries that must be overcome in order to reach this goal. In conclusion, globally, work must continue to ensure national policies are in place to support screening, linkage to care and affordable treatment in order to eliminate HCV.
© 2018 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  clinical; economics; extrahepatic manifestations; patient-reported outcomes

Mesh:

Substances:

Year:  2018        PMID: 30398294     DOI: 10.1111/jvh.13005

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

1.  Association Between Time to First RNA-Negative Test Result Among People With Hepatitis C Virus Infection and Homelessness or Testing at a Correctional or Substance Use Treatment Facility, New York City.

Authors:  Miranda S Moore; Angelica Bocour
Journal:  Public Health Rep       Date:  2021-10-25       Impact factor: 3.117

Review 2.  Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population.

Authors:  Arun Rajasekaran; Ricardo A Franco; Edgar T Overton; Brendan M McGuire; Graham C Towns; Jayme E Locke; Deirdre L Sawinski; Emmy K Bell
Journal:  Kidney Int Rep       Date:  2021-04-25

3.  Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals.

Authors:  Julia L Marcus; Michael J Silverberg; Jennifer O Lam; Leo B Hurley; Jennifer B Lai; Varun Saxena; Suk Seo; Scott Chamberland; Charles P Quesenberry; Jamila H Champsi; Joanna Ready; Elizabeth Y Chiao
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-09-28       Impact factor: 4.090

4.  A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South.

Authors:  Jacqueline E Sherbuk; Alexa Tabackman; Kathleen A McManus; Terry Kemp Knick; Julie Schexnayder; Tabor E Flickinger; Rebecca Dillingham
Journal:  Harm Reduct J       Date:  2020-09-18

5.  Does access to care play a role in liver cancer survival? The ten-year (2006-2015) experience from a population-based cancer registry in Southern Italy.

Authors:  Walter Mazzucco; Francesco Vitale; Sergio Mazzola; Rosalba Amodio; Maurizio Zarcone; Davide Alba; Claudia Marotta; Rosanna Cusimano; Claudia Allemani
Journal:  BMC Cancer       Date:  2021-03-24       Impact factor: 4.430

6.  Disparities in Hepatitis C Linkage to Care in the Direct Acting Antiviral Era: Findings From a Referral Clinic With an Embedded Nurse Navigator Model.

Authors:  Jacqueline E Sherbuk; Kathleen A McManus; Terry Kemp Knick; Chelsea E Canan; Tabor Flickinger; Rebecca Dillingham
Journal:  Front Public Health       Date:  2019-11-27

7.  Generation of Combinatorial Lentiviral Vectors Expressing Multiple Anti-Hepatitis C Virus shRNAs and Their Validation on a Novel HCV Replicon Double Reporter Cell Line.

Authors:  Hossein M Elbadawy; Mohi I Mohammed Abdul; Naif Aljuhani; Adriana Vitiello; Francesco Ciccarese; Mohamed A Shaker; Heba M Eltahir; Giorgio Palù; Veronica Di Antonio; Hanieh Ghassabian; Claudia Del Vecchio; Cristiano Salata; Elisa Franchin; Eleonora Ponterio; Saleh Bahashwan; Khaled Thabet; Mekky M Abouzied; Ahmed M Shehata; Cristina Parolin; Arianna Calistri; Gualtiero Alvisi
Journal:  Viruses       Date:  2020-09-18       Impact factor: 5.048

8.  Emergency department targeted screening for hepatitis C does not improve linkage to care.

Authors:  Inbal Houri; Noya Horowitz; Helena Katchman; Yael Weksler; Ofer Miller; Liat Deutsch; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2020-08-28       Impact factor: 5.742

9.  The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data.

Authors:  Mark Sulkowski; Raluca Ionescu-Ittu; Dendy Macaulay; Yuri Sanchez-Gonzalez
Journal:  Adv Ther       Date:  2020-09-14       Impact factor: 3.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.